Agents and methods to elicit anti-tumor immune response
Inventors
Gu, Hua • Hodes, Richard • Chiang, Jeffrey J. • Jang, Ihnkyung
Assignees
Columbia University in the City of New York • US Department of Health and Human Services
Publication Number
US-10822588-B2
Publication Date
2020-11-03
Expiration Date
2027-09-13
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. The invention provides uses of such cells in methods for inducing or enhancing an anti-tumor immune response in a subject. These methods comprise: (a) providing a cell population, from a subject or from another source, which comprises CD8+ T cells, (b) reducing Cbl-b activity in the CD8+ T-cells, (c) administering the cells of step (b) to the subject. The invention provides methods for making CD8+ T cells that do not require stimulation through a co-receptor in order for the cell to become activated or proliferated in response to contact via its T cell receptor. Such methods are based upon reducing function of Cbl-b. The invention also provides methods for identifying agents which affect Cbl-b expression or activity.
Core Innovation
The invention provides an isolated, purified population of human cells comprising CD8+ T cells with reduced Cbl-b activity. It includes methods for inducing or enhancing an anti-tumor immune response by providing a cell population comprising CD8+ T cells, reducing Cbl-b activity in these cells, and administering them to a subject. The methods generate CD8+ T cells that do not require co-receptor stimulation to become activated or proliferate upon T cell receptor engagement, achieved by reducing or eliminating the function or expression of Cbl-b.
The problem being solved is that many tumors evade immune surveillance despite the presence of tumor antigen-specific cytotoxic T lymphocytes (CTLs). Tumors often lack costimulatory ligands required for full T cell activation, leading to T cell anergy or non-responsiveness. Existing immunotherapy approaches have limited success due to tumor-mediated suppression and absence of effective T cell co-stimulation. Thus, there is a need for methods to induce or enhance anti-tumor immune responses independent of costimulatory signals.
The invention addresses this by showing that reduction or ablation of Cbl-b in CD8+ T cells permits activation and proliferation independent of co-stimulation, such as via CD28, overcoming tumor immune evasion. This enables generation of "super killer" CTLs that can effectively respond to tumors, including those producing suppressive factors like TGF-beta or lacking costimulatory molecules. The invention also provides methods to identify agents that modulate Cbl-b expression or activity, and demonstrates the use of Cbl-b deficient CD8+ T cells in adoptive transfer therapy to eradicate established tumors.
Claims Coverage
The claims disclose multiple inventive features related to methods for making and using CD8+ T cells with reduced Cbl-b activity for anti-tumor immune responses and therapeutic applications.
Reduction of Cbl-b activity in CD8+ T cells by siRNA from peripheral blood
The method involves providing CD8+ T cells from peripheral blood and reducing Cbl-b activity in these cells by introducing an siRNA targeting Cbl-b, specifically the siRNA comprising the sequence of SEQ ID NO:1, resulting in CD8+ T cells that do not require co-stimulation to become activated and proliferate.
Methods for inducing anti-tumor immune response by administering CD8+ T cells with reduced Cbl-b activity
The method includes providing CD8+ T cells from peripheral blood, reducing Cbl-b activity by siRNA of SEQ ID NO:1, and administering these modified cells to a subject to induce anti-tumor immunity, particularly against solid tumors expressing MHC-I antigens recognized by CTLs, including metastatic tumors.
Adoptive tumor immunotherapy using CD8+ T cells with reduced Cbl-b activity
Adoptive transfer therapy comprises isolating CD8+ T cells from peripheral blood, reducing Cbl-b activity via siRNA (SEQ ID NO:1), optionally stimulating proliferation after reduction, and administering these cells to a subject with one or more solid tumors to treat or promote immune rejection.
Isolated populations of CD8+ T cells with reduced Cbl-b activity for cancer treatment
Provides isolated CD8+ T cell populations from peripheral blood of subjects having solid tumors, having reduced Cbl-b activity by introduction of siRNA targeting Cbl-b (SEQ ID NO:1). These populations can be included in pharmaceutical compositions used for treating cancer or immune rejection of tumors, including metastatic tumors.
The claims collectively cover methods for producing CD8+ T cells with reduced Cbl-b activity by siRNA from peripheral blood and their therapeutic use via adoptive transfer to induce anti-tumor immune responses and treat solid tumors, alongside compositions comprising such modified CD8+ T cells.
Stated Advantages
Cbl-b deficient or ablated CD8+ T cells can be activated and proliferate without requiring co-stimulation, enabling them to respond to tumors lacking costimulatory signals.
Adoptive transfer of Cbl-b deficient CD8+ T cells effectively eradicates established tumors, including those with strong or weak antigenicity and metastatic tumors.
Cbl-b deficient CD8+ T cells are resistant to tumor-derived immunosuppressive factors such as TGF-beta, enhancing their anti-tumor efficacy.
Reduction or ablation of Cbl-b eliminates the need for large amounts of exogenous cytokines or costimulatory vaccines in immunotherapy, simplifying treatment.
Modification of tumor-infiltrating lymphocytes to reduce Cbl-b activity enhances their responsiveness to tumor antigens and enables generation of a potent therapeutic "super killer" T cell population.
Documented Applications
Using isolated CD8+ T cells with reduced Cbl-b activity to induce or enhance anti-tumor immune responses in subjects with tumors.
Adoptive transfer immunotherapy of cancer by administering CD8+ T cells with reduced Cbl-b activity to treat solid tumors, including metastatic tumors.
Generating CD8+ T cells that do not require co-stimulation for activation or proliferation for cancer immunotherapy.
Screening for agents that modulate Cbl-b expression or activity to identify potential tumor immunotherapy agents.
Interested in licensing this patent?